Literature DB >> 8133045

Regulation of expression of the IL-1 receptor antagonist (IL-1ra) gene by products of the human cytomegalovirus immediate early genes.

J N Kline1, L J Geist, M M Monick, M F Stinski, G W Hunninghake.   

Abstract

Human cytomegalovirus (HCMV), which is a major cause of morbidity and mortality in immunosuppressed patients, can itself alter immune function. It has previously been shown that HCMV immediate early (IE) gene products regulate the IL-1 beta promoter. The purpose of these studies was to determine whether HCMV IE gene products regulate expression of the IL-1 receptor antagonist (IL-1ra) gene. THP-1 cells, a myelomonocytic cell line, were transfected with a plasmid containing one or more of the HCMV IE genes downstream of the HCMV major immediate early promoter, or with a control plasmid. IL-1 beta and IL-1ra protein secretion was evaluated by ELISA, and expression of the mRNA for the cytokines was examined by means of Northern blot analysis. The HCMV IE1+2 gene products were found to increase expression of the mRNA for both IL-1 beta and IL-1ra; however, only the IL-1ra protein was released in increased amounts. The individual HCMV IE gene products had different effects on expression of the IL-1ra gene; the HCMV IE1 gene product down-regulated expression of the IL-1ra gene, whereas the IE2 gene product up-regulated expression of the IL-1ra gene. Thus, HCMV IE gene products can either up-regulate or down-regulate expression of the IL-1ra gene, depending on which IE genes are expressed in monocytes-macrophages. This study adds to the understanding of how HCMV can alter immune function during both active and latent infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8133045

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  The carboxyl-terminal region of human cytomegalovirus IE1491aa contains an acidic domain that plays a regulatory role and a chromatin-tethering domain that is dispensable during viral replication.

Authors:  Jens Reinhardt; Geoffrey B Smith; Christopher T Himmelheber; Jane Azizkhan-Clifford; Edward S Mocarski
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-kappaB-binding sites of the interleukin-8 gene.

Authors:  T Murayama; Y Ohara; M Obuchi; K S Khabar; H Higashi; N Mukaida; K Matsushima
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Cytomegalovirus IE2 protein stimulates interleukin 1beta gene transcription via tethering to Spi-1/PU.1.

Authors:  N Wara-aswapati; Z Yang; W R Waterman; Y Koyama; S Tetradis; B K Choy; A C Webb; P E Auron
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

4.  Human cytomegalovirus inhibits transcription of the CC chemokine MCP-1 gene.

Authors:  A J Hirsch; T Shenk
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  CREB and CREB-binding proteins play an important role in the IE2 86-kilodalton protein-mediated transactivation of the human cytomegalovirus 2.2-kilobase RNA promoter.

Authors:  R Schwartz; B Helmich; D H Spector
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  The 5' Untranslated Region of the Major Immediate Early mRNA Is Necessary for Efficient Human Cytomegalovirus Replication.

Authors:  Kyle C Arend; Erik M Lenarcic; Nathaniel J Moorman
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

7.  Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-γ.

Authors:  Theresa Knoblach; Benedikt Grandel; Jana Seiler; Michael Nevels; Christina Paulus
Journal:  PLoS Pathog       Date:  2011-04-14       Impact factor: 6.823

8.  Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells.

Authors:  B Bodaghi; T R Jones; D Zipeto; C Vita; L Sun; L Laurent; F Arenzana-Seisdedos; J L Virelizier; S Michelson
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.